Cardiometabolic Monitoring: Numbers Need Dialysis Context

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Avoid hypoglycemia and treatment burden while pursuing realistic cardiovascular and functional goals. A better laboratory number is not the sole measure of benefit.

Read metabolic results in dialysis context. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Read metabolic results in dialysis context. . HbA1c, nutrition and cardiovascular treatment evidence require context; a measured change is not automatically an indication. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Risk is high, evidence differs

Lipid and glucose abnormalities occur in a setting of inflammation, altered clearance, vascular disease, and competing risks.

Investigate HbA1c–glucose disagreement

Recent transfusion, ESA treatment, iron therapy, or shortened red-cell survival may make HbA1c misleading. Compare with measured glucose and hypoglycemia symptoms; consider CGM when useful. Do not intensify insulin solely because a biomarker and the clinical glucose pattern disagree.

Use complementary information

Review hypoglycemia, nutritional intake, treatment-day patterns, and available glucose monitoring. Do not intensify treatment from one surrogate alone.

Separate statin initiation from continuation

KDIGO lipid guidance generally discourages initiating a statin solely for primary prevention in dialysis-dependent CKD but supports continuation when already used at dialysis initiation. An acute coronary event creates a different individualized discussion. Do not translate a general LDL target into automatic escalation for every dialysis patient.

Chair-side observations

Report recurrent low glucose, poor intake, dizziness, changes in medicines, and barriers to monitoring. Coordinate diet and medication timing with the care team.

Focus on outcomes

Avoid hypoglycemia and treatment burden while pursuing realistic cardiovascular and functional goals. A better laboratory number is not the sole measure of benefit.

Supporting evidence

Continue learning